Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cell-free autologous fat extract (FE) is a bioactive liquid derived from a patient's own adipose tissue through mechanical emulsification and centrifugation. The process is designed to remove all cellular components, including adipocytes and stem cells, while concentrating a rich array of endogenous growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and transforming growth factor-beta (TGF-β). These components facilitate tissue regeneration by promoting angiogenesis, stimulating fibroblast proliferation, and modulating the extracellular matrix. FE is primarily investigated for the treatment of atrophic scars and skin rejuvenation, often administered via local injection to improve skin texture and volume, sometimes in combination with hyaluronic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cell-free autologous fat extract.